Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CLDI NASDAQ:FMTX NYSE:IKT NYSE:PRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDICalidi Biotherapeutics$5.01-13.0%$5.43$2.43▼$46.68$15.16M1.15655,731 shs164,927 shsFMTXForma Therapeutics$20.01$20.00$4.95▼$20.68$957.54M-0.94847,595 shs1 shsIKTInhibikase Therapeutics$1.43-7.7%$1.82$1.12▼$4.20$106.31M0.9197,512 shs142,885 shsPRMEPrime Medicine$3.79+3.0%$3.10$1.11▼$5.17$509.74M2.392.47 million shs3.59 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDICalidi Biotherapeutics-13.02%-29.27%-40.36%-9.02%-74.23%FMTXForma Therapeutics0.00%0.00%0.00%0.00%0.00%IKTInhibikase Therapeutics-7.74%-5.92%-29.21%-28.50%+12.60%PRMEPrime Medicine+2.99%-6.19%-16.52%+191.54%-13.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDICalidi Biotherapeutics0.168 of 5 stars0.02.00.00.01.10.00.6FMTXForma TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIKTInhibikase Therapeutics1.6425 of 5 stars3.33.00.00.00.00.01.3PRMEPrime Medicine3.8747 of 5 stars4.41.00.00.03.65.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDICalidi Biotherapeutics 0.00N/AN/AN/AFMTXForma Therapeutics 0.00N/AN/AN/AIKTInhibikase Therapeutics 2.50Moderate Buy$6.50354.55% UpsidePRMEPrime Medicine 2.75Moderate Buy$8.92135.27% UpsideCurrent Analyst Ratings BreakdownLatest FMTX, PRME, CLDI, and IKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.007/16/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.005/27/2025PRMEPrime MedicineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $1.505/20/2025PRMEPrime MedicineJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.005/20/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/19/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.00(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDICalidi BiotherapeuticsN/AN/AN/AN/A($2.32) per shareN/AFMTXForma Therapeutics$100.56M9.52N/AN/A$10.51 per share1.90IKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/APRMEPrime Medicine$3.85M132.54N/AN/A$1.37 per share2.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDICalidi Biotherapeutics-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/AFMTXForma Therapeutics-$172.96M-$4.00N/AN/AN/AN/A-39.68%-35.33%N/AIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/APRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDICalidi BiotherapeuticsN/AN/AN/AN/AN/AFMTXForma TherapeuticsN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/APRMEPrime Medicine$1.4538.15%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDICalidi BiotherapeuticsN/A0.190.19FMTXForma TherapeuticsN/A12.7412.74IKTInhibikase TherapeuticsN/A0.850.85PRMEPrime MedicineN/A6.506.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDICalidi Biotherapeutics12.53%FMTXForma Therapeutics87.39%IKTInhibikase Therapeutics3.81%PRMEPrime Medicine70.37%Insider OwnershipCompanyInsider OwnershipCLDICalidi Biotherapeutics6.70%FMTXForma Therapeutics5.79%IKTInhibikase Therapeutics7.30%PRMEPrime Medicine22.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDICalidi Biotherapeutics383.03 million20.04 millionN/AFMTXForma Therapeutics16647.85 million45.08 millionNot OptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionablePRMEPrime Medicine234134.50 million100.38 millionOptionableFMTX, PRME, CLDI, and IKT HeadlinesRecent News About These CompaniesPrime Medicine, Inc.: Strong Buy Rating Backed by Promising Pipeline and Robust Financial PositionAugust 8 at 4:27 PM | tipranks.comPRME Revenue Misses by 73%August 8 at 9:02 AM | aol.comAPrime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue EstimatesAugust 7 at 10:11 AM | zacks.comPrime Medicine Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 7 at 8:00 AM | globenewswire.comPrime Medicine (NYSE:PRME) Trading Down 6.7% - Here's What HappenedAugust 6 at 1:43 PM | marketbeat.comPrime Medicine (NYSE:PRME) Shares Gap Up Following Insider Buying ActivityAugust 6 at 2:13 AM | americanbankingnews.comPrime Medicine Holds Special Stockholder MeetingAugust 5, 2025 | tipranks.comPrime Medicine (NYSE:PRME) Shares Gap Up on Insider Buying ActivityAugust 5, 2025 | marketbeat.comFriday’s Insider Trades: Key Buys and Sells in US Stocks RevealedAugust 4, 2025 | investing.comArch Venture Partners Xii, Llc Purchases 3,030,300 Shares of Prime Medicine, Inc. (NYSE:PRME) StockAugust 2, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Major Shareholder Arch Venture Partners Xii, Llc Purchases 3,030,300 SharesAugust 2, 2025 | insidertrades.comPrime Medicine Halts Sales Agreement ProspectusAugust 1, 2025 | theglobeandmail.comPrime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesAugust 1, 2025 | finance.yahoo.comPrime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesAugust 1, 2025 | globenewswire.comPrime Medicine (NYSE:PRME) Shares Gap Down - Here's WhyAugust 1, 2025 | marketbeat.comPrime Medicine stock falls after pricing public offeringAugust 1, 2025 | za.investing.comJonesTrading Maintains a Buy on Prime Medicine (PRME)August 1, 2025 | msn.comPrime Medicine (NYSE:PRME) Trading Up 6.9% - Here's WhyJuly 31, 2025 | marketbeat.comPrime Medicine Announces Pricing of Public OfferingJuly 30, 2025 | globenewswire.comPrime Drink Group Extends Expiry Date of Its Rights Offering and Announces Delay in Filing Annual Financial StatementsJuly 30, 2025 | globenewswire.comPrime Medicine (NYSE:PRME) Trading Down 8.9% - Here's WhyJuly 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFMTX, PRME, CLDI, and IKT Company DescriptionsCalidi Biotherapeutics NYSE:CLDI$5.01 -0.75 (-13.02%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$5.15 +0.14 (+2.79%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.Forma Therapeutics NASDAQ:FMTXForma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.Inhibikase Therapeutics NYSE:IKT$1.43 -0.12 (-7.74%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.44 +0.01 (+0.35%) As of 08/8/2025 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Prime Medicine NYSE:PRME$3.79 +0.11 (+2.99%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$3.77 -0.02 (-0.53%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
